Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Andrew H who wrote (12833)	12/24/1997 8:55:00 AM
From: Henry Niman	Read Replies (2) \| Respond to of 32384

Andy, Pierre Chambon has been doing basic research on non-polypeptide hormone receptors for many years. This work is not directly associated with LGND, although I think that Chambon was/is on LGND's Scientific Advisory Board. I believe that the above work relates to RARs and as you know, LGND has very extensive programs in that area. I really haven't heard much about a neurobiology effort, but I said some time ago that the area could be very rewarding for LGND. I do think that LGND has a very active estrogen program that targets Alzheimer and memory, and I expect to hear more about those efforts in the near term. When LGND acquired GLYC, John Groome went on LGND's board. I thought that such a move may have been related to a neuroscience effort, but have not seen anything in this area for retinoid/rexinoids, although I'm fairly certain that there will be significant indications and applications. Tomorrow I am heading for Florida for a week (for a major soccer tournament home.att.net and to start some serious thinking about your two bottles of wine). Happy holidays to all.